25-NHL-45-CC (CA0731003): A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator s Choice in Participants with Relapsed/Refractory Follicular Lymphom

Grants and Contracts Details

StatusActive
Effective start/end date8/28/258/28/27

Funding

  • Celgene: $2.00